Stuttgart - Delayed Quote EUR

Krystal Biotech, Inc. (4KB.SG)

116.40
-0.35
(-0.30%)
At close: May 16 at 9:33:39 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
333,448
290,515
50,699
0
0
Cost of Revenue
22,670
20,061
3,094
0
0
Gross Profit
310,778
270,454
47,605
0
0
Operating Expense
177,222
167,259
144,832
120,196
68,275
Operating Income
133,556
103,195
-97,227
-120,196
-68,275
Net Non Operating Interest Income Expense
29,465
29,661
22,624
5,221
-1,295
Other Income Expense
--
-37,500
87,500
-25,000
--
Pretax Income
138,021
95,356
12,897
-139,975
-69,570
Tax Provision
14,061
6,197
1,965
0
0
Net Income Common Stockholders
123,960
89,159
10,932
-139,975
-69,570
Diluted NI Available to Com Stockholders
123,960
89,159
10,932
-139,975
-69,570
Basic EPS
4.33
3.12
0.40
-5.49
-3.13
Diluted EPS
4.17
3.00
0.39
-5.49
-3.13
Basic Average Shares
28,722
28,592
27,154
25,492
22,196.85
Diluted Average Shares
29,885
29,740
27,752
25,492
22,196.85
Total Operating Income as Reported
108,556
65,695
-109,727
-145,196
-68,275
Total Expenses
199,892
187,320
147,926
120,196
68,275
Net Income from Continuing & Discontinued Operation
123,960
89,159
10,932
-139,975
-69,570
Normalized Income
146,413.10
124,221.95
-63,236.41
-114,975
-69,570
Interest Income
--
29,661
22,624
5,221
197
Interest Expense
--
--
0
0
1,492
Net Interest Income
29,465
29,661
22,624
5,221
-1,295
EBIT
133,556
103,195
-97,227
-120,196
-68,078
EBITDA
140,295
109,909
-91,316
-116,811
-66,229
Reconciled Cost of Revenue
22,670
20,061
3,094
0
0
Reconciled Depreciation
6,739
6,714
5,911
3,385
1,849
Net Income from Continuing Operation Net Minority Interest
123,960
89,159
10,932
-139,975
-69,570
Total Unusual Items Excluding Goodwill
-25,000
-37,500
87,500
-25,000
0
Total Unusual Items
-25,000
-37,500
87,500
-25,000
0
Normalized EBITDA
165,295
147,409
-178,816
-91,811
-66,229
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,546.90
-2,437.05
13,331.59
0
0
12/31/2021 - 11/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SRZN Surrozen, Inc.
7.10
+3.65%
 
CTNM Contineum Therapeutics, Inc.
3.5100
-10.91%
 
ENGN enGene Holdings Inc.
3.4500
+1.47%
 
INTS Intensity Therapeutics, Inc.
0.4200
-16.00%
 
CLGN CollPlant Biotechnologies Ltd.
1.7300
-1.14%
 
KLRS Kalaris Therapeutics, Inc.
3.4800
-1.69%
 
OKUR OnKure Therapeutics, Inc.
2.0000
-2.91%
 
AVTX Avalo Therapeutics, Inc.
3.9100
+1.30%
 
ACRV Acrivon Therapeutics, Inc.
1.1500
+4.55%
 
PRTA Prothena Corporation plc
7.18
+6.92%